Market Overview

UPDATE: Bank of America Reiterates Buy Rating, Raises PT on Mylan on Announced Agila Acquisition

Related MYL
US Stock Futures Down Ahead Of Industrial Production Report
Mylan In Pact With Gilead To Accelerate Access To Hepatitis C
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

In a report published Monday, Bank of America reiterated its Buy rating on Mylan (NASDAQ: MYL), and slightly raised its price target from $33.00 to $34.00.

Bank of America noted, “On 2/27, MYL announced that it is buying Strides' injectables unit, Agila, for $1.6bn in cash. Our initial attempt at adding Agila to our MYL model generally validates MYL's assumption that the deal could be accretive quickly. Our new 2014/15E adj. EPS are $3.52/$3.50 vs. $3.38/$3.33 (or accretion of 4%/5%), and we are tweaking our DCF-based PO up to $34 (from $33). As we stated, we see this transaction as an exciting platform (existing products + pipeline) for MYL to dramatically accelerate its position in the strategically important injectables space, which has seen some FDA-related missteps by competitors (HSP, Ben Venue, TEVA, etc.), especially in the US.”

Mylan closed on Friday at $30.10.

Latest Ratings for MYL

DateFirmActionFromTo
Sep 2014ISI GroupInitiates Coverage on
Aug 2014RBC CapitalDowngradesOutperformSector Perform
Aug 2014CitigroupMaintainsNeutral

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters